4月27日 - ** Oruka Therapeutics（ORKA.O）股价盘前上涨31.77%，报90.96美元
** 该公司表示，其试验性注射用银屑病治疗药物在16周时，有63.5%的患者实现了 (link) 完全皮肤清除，达到了中期临床试验的主要目标
** 补充称，单克隆抗体ORKA-001耐受性良好，安全性特征与安慰剂相似
** Oruka计划于2026年下半年公布长期数据，包括所有患者的28周疗效数据以及部分受试者的52周随访数据
** ORKA-001目前正用于治疗中重度斑块型银屑病患者，该慢性自身免疫性疾病会导致皮肤出现瘙痒性鳞屑斑块
** 截至上一交易日收盘，该股年内累计涨幅约128%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.